以分子靶向治疗为基础的联合治疗，是目前晚期肝癌有效的治疗模式。本文作者对1例肝细胞癌术后复发、经肝动脉灌注化疗栓塞治疗进展的晚期患者，隔日给予小剂量阿帕替尼（250 mg）治疗，取得良好疗效。

[1] 李雪松,夏锋.晚期肝癌治疗方案选择[J].肝胆外科杂志,2014,22(4):250-254.
[2] 罗以,周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:611-613.
[3] 中国抗癌协会肝癌专业委员会.原发性肝癌规范化诊治的专家共识[J].中华肝脏病杂志,2009,17(6):483-492.
[4] TIAN S,QUAN H,XIE C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci,2011,102(7):1374-1380.
[5] 秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015,20(9):841-847.
[6] 赵明芳.阿帕替尼治疗晚期非小细胞肺癌一例[J].中华医学信息导报,2015,30(16):18.
[7] JIN L,ZHAO X,LEI C,et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer,2010,10(1):529.
[8] LI Y,ZHENG Y B,ZHAO W,et al.Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma[J].Med Oncol,2013,30(4):730.